ECM
SCNI

ExodusPoint Capital Management’s Scinai Immunotherapeutics SCNI Stock Holding History

ExodusPoint Capital Management’s Portfolio SCNI Stock Details SCNI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-315
Closed -$74K – 2620
2021
Q4 		$74K Buy
+315
New +$65K ﹤0.01% 1993

Other funds holding SCNI

Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $374B AUM 17.66% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TPWA
TRUE Private Wealth Advisors Salem, Oregon $1.05B AUM 19.14% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

ExodusPoint Capital Management's SCNI Position: Q1 2022 in Review

ExodusPoint Capital Management sold out of Scinai Immunotherapeutics (SCNI) in Q1 2022, closing a stake of 315 shares — an estimated $74K sold.

ExodusPoint Capital Management first reported a position in SCNI in Q4 2021 and held it in 1 quarter. The position peaked at $74K in Q4 2021. 18 funds tracked by Wall St. Rank hold SCNI as of Q1 2022.

  • ExodusPoint Capital Management reported no remaining Scinai Immunotherapeutics position as of Q1 2022 after selling out during the quarter.
  • ExodusPoint Capital Management sold 315 Scinai Immunotherapeutics shares in Q1 2022, an estimated $74K.
  • ExodusPoint Capital Management first reported a position in Scinai Immunotherapeutics in Q4 2021 and held it in 1 quarter.
  • ExodusPoint Capital Management's Scinai Immunotherapeutics position peaked at $74K in Q4 2021.
  • 18 funds tracked by Wall St. Rank held Scinai Immunotherapeutics as of Q1 2022.

Based on ExodusPoint Capital Management's 13F filing for Q1 2022, filed 13 May 2022.